Dr Joleen Hubbard discusses non-surgical management of early stage rectal cancer

Dr Joleen Hubbard is Deputy Director of Clinical Research and Academic Affairs for the Allina Health Cancer Institute in Minneapolis, Minnesota.  She was previously Assistant Professor of Medical Oncology at Mayo Clinic. She completed medical school and residency at the University of Minnesota and haematology/oncology training at Mayo Clinic, Rochester, Minnesota. Dr Hubbard specialises in the treatment of gastrointestinal cancers, focusing on colorectal cancer. Dr Hubbard is the PI of several phase I clinical trials, investigating novel agents for gastrointestinal cancers. Her research interests also include geriatric oncology with a special interest in clinical and biologic markers of frailty. She serves as a member of the Cancer in the Elderly, as well as the Health Reported Outcomes and Translational Research committees for the North American Alliance of Clinical Trials in Oncology Network. 

Assoc. Prof. Joleen Hubbard has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Advisory boards: Bayer, Merck, BeiGene, Incyte

Research funding to institution: Merck, Boston Biomedical, Treos Bio, Senhwa Pharmaceuticals, Bayer, Incyte, TriOncology, Seattle Genetics, Hutchison MediPharma, Pionyr Immunotherapeutics, Trovogene, G1 Therapeutics, Roche

Programme summary
Watch the video now
Share this programme
This educational programme is supported by an Independent Educational Grant from Bayer
Supporter Acknowledgement
This educational programme is supported by an Independent Educational Grant from Bayer
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
GI CONNECT

GI CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from Bayer, Ipsen, BeiGene Europe and Pierre Fabre Laboratories.  

Meet the experts Independent IME approved

Other programmes of interest

publication Publication
Oncology 
Emerging molecular testing paradigms in NSCLC management

Experts
Prof. Frédérique Penault-Llorca, Prof. Mark Socinski
  • download Downloadable
    Resources
  • clock 20 MIN
  • calendar Apr 2025

Educational programme supported by an Independent Educational Grant from Bayer.
animated-video Animated Video
Oncology 
Elacestrant in ER+/HER2- metastatic breast cancer with ESR1-mut tumors

An overview of the EMERALD subgroup analyses

Experts
Prof. Javier Cortés
  • download Downloadable
    Resources
  • clock 8 MIN
  • calendar Apr 2025

This programme has been sponsored by Menarini Stemline and is intended for healthcare professionals only.
podcast Podcast
Oncology 
The HER2 diagnostic and treatment landscape in NSCLC: Episode 1

A medical oncologist and a pathologist share their perspectives on best practices in identifying HER2-directed NSCLC

Experts
Prof. Fernando López-Ríos, MD, PhD, Dr Devika Das, Oncology Brothers (Moderators)
Endorsed by
ICAN international cancer advocacy network Biomarker Collaborative Exon20group
  • download Downloadable
    Resources
  • clock 20 MIN
  • calendar Apr 2025

Educational programme supported by an Independent Educational Grant from Bayer.
publication Publication
Oncology 
Survey on the evolving role of the oncology nurse in the USA

Survey findings presented at ONS 2025 and published in the journal Healthcare

Experts
Nina Grenon, Natasha Pinheiro, Karen Waldrop, Brittni Prosdocimo
  • download Downloadable
    Resources
  • clock 7 MIN
  • calendar Apr 2025

Educational programme supported by an Independent Educational Grant from Bayer.
video Video
Oncology 
The patient perspective: Living with NSCLC driven by a rare alteration

What to know, what to expect, and where to find support

Experts
Marcia Horn
Endorsed by
ICAN international cancer advocacy network Biomarker Collaborative Exon20group
BRAF Bombers PD-L1 Amplifieds MET crusaders
  • clock 8 MIN
  • calendar Apr 2025

Educational programme supported by an Independent Educational Grant from Boehringer Ingelheim.
animated-video Animated Video
Oncology 
Chemotherapy strategies for metastatic pancreatic ductal adenocarcinoma

Optimising 1st and 2nd line treatment

Experts
Prof. Eileen O'Reilly, Prof. Efrat Dotan
Endorsed by
ICAN international cancer advocacy network DiCE PanCAN
National Pancreas Foundation
  • download Downloadable
    Resources
  • clock 6 MIN
  • calendar Apr 2025

Educational programme supported by an Independent Educational Grant from Ipsen USA.